Navigation Links
Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference
Date:2/13/2009

in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Micromet has granted an exclusive option to Bayer Schering Pharma AG to license a BiTE antibody against an undisclosed solid tumor target. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical d
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
2. Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference
3. Micromet, Inc. Reports Second Quarter 2008 Financial Results
4. Micromet, Inc. Reports First Quarter 2008 Financial Results
5. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
6. Micromets BiTE(R) Antibodies Reveal Unique Mode of Action
7. Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
9. Social Security Disability Applicants Increase Chances for Benefits with Representation
10. NeoGenomics to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
11. Hill-Rom to Present at the Canaccord Adams Musculoskeletal Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... July 13, 2014 Chromatography system ... components from various types of biological samples such ... the sample mixture into two phase, namely mobile ... mobile phase run over the stationary phase, followed ... components that provide the separation of mixture. Chromatography ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized for ... wells as to maintain soil quality. The application of ... a dominant revenue generator for manufacturers in future. The ... costs has led to the adoption of micro irrigation ... caused massive demand for micro irrigation systems, as they ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 According ... Processing and Computing Market by Component (processor, GPU, ... Automotive, MDA, Medical), and Geography - Forecast and ... Heterogeneous Mobile Processing & Computing Market is expected ... a CAGR of 20.75% from 2014 to 2020. ...
(Date:7/13/2014)... The Pearland, Texas location of The Little ... four months to 12 years of age that offers everything ... parties and Summer Camps, is now under new ownership. , ... after spending over six years at The Little Gym ... , Berry has over ten years of experience working ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Max ... Famer, Chris Mullin, will be the featured guest at ... 26th in Puerto Rico. Attendees will learn about ... participate in two exhibition basketball games and perform in ... supplier of health- and energy-boosting supplements , has ...
Breaking Medicine News(10 mins):Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 2Health News:North America Chromatography Systems Market Is Expected to Reach $6593.4 Million by 2018 - New Report by MicroMarket Monitor 3Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... common cause of death and disability in children and adolescents, ... a new study by UCLA researchers, the effects of a ... can linger for years. , Reporting in the May ... author and a UCLA post-doctoral fellow, and senior author Robert ...
... Ky., May 13 We,ve all made mistakes: bell bottoms, scrunchies ... in the past. Thanks to advances in skin care and ... In fact, it,s downright dangerous. According to the National Cancer ... in 2009 resulting in about 1,000 deaths. Skin cancer is ...
... was recently recognized by the Art Directors Club ... Awards Exhibition.ScienceFirst graphic designer Michelle Feingold won a ... a speaker training creative platform for a top-tier, ... received Certificates of Excellence. One of the entries ...
... combination medication approved with the extended-release form of ... Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, ... announced that the U.S. Food and Drug Administration ... medication ACTO plus met(R) (pioglitazone HCl and ...
... ,Covering All the Bases® Hitting Challenge, during Major League Baseball,s ,4ALS ... famous ,Luckiest Man, farewell speech as he battled the disease that ... ... (Vocus) May 13, 2009 -- The ALS Association,s is launching the ...
... technology leader in email and file archiving ... and storage management, today announces the release ... Suite with SharePoint Archiving at Microsoft TechEd ... Email & File Archive Enterprise Suite with ...
Cached Medicine News:Health News:UCLA study shows traumatic brain injury haunts children for years 2Health News:Get Sun Smart at the Spa 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 4Health News:70th Anniversary of Lou Gehrig's Farewell Speech: The ALS Association Launches the 'Covering All the Bases Hitting Challenge' 2Health News:70th Anniversary of Lou Gehrig's Farewell Speech: The ALS Association Launches the 'Covering All the Bases Hitting Challenge' 3Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 2Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 3Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 4Health News:MessageSolution Releases Email & File Archive Enterprise Suite with SharePoint Archiving at Microsoft TechEd North America 2009 5
(Date:7/10/2014)... Virginia , 11. Juli 2014 ... von Kameras für die molekulare Bildgebung, ... hat heute die CE-Zulassung für sein ... CE-Zeichen kann Dilon das Produkt jetzt ... auf den Großteil der europäischen Länder ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... MESA, Ariz., Dec. 6, 2011   Ulthera ... device company pioneering aesthetic and medical applications ... today announced that it has named Greg ... newly created position at Ulthera. ...
... Industries, Inc. (OTC.PK:PDMI) announced that it is continuing to move ... the limited working capital and market concerns it has had ... the mettle of Paradigm, its shareholders and remaining loyal employees. ... close, Paradigm remains hopeful it will see the DTC "chill" ...
Cached Medicine Technology:Ulthera Appoints Greg Waller as Chief Financial Officer 2Paradigm Business Update as of November 30, 2011 2
... The 9101-7.5 convex array is designed with ... resolution obtained with this multi-frequency transducer is ... in need of quick and accurate diagnoses. ... versatility you need, and allows you to ...
Compact, bench-top analyser with minimal water volume requirements and easy waste management....
... light source is a superior choice for ... surgery, headlamps, and dental curing. This is ... light weight, compact and cost competitve with ... light source utilizes the latest in Cermax ...
... AtheNA Multi-Lyte Test System* is a ... simultaneously perform multiple assays from a ... It offers a simple and streamlined ... providing improved clinical sensitivity and comparable ...
Medicine Products: